PADOAN, ROBERTO
 Distribuzione geografica
Continente #
NA - Nord America 3.476
AS - Asia 2.701
EU - Europa 1.447
SA - Sud America 431
AF - Africa 407
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 16
Totale 8.515
Nazione #
US - Stati Uniti d'America 3.233
SG - Singapore 752
VN - Vietnam 596
IT - Italia 533
CN - Cina 450
BR - Brasile 275
HK - Hong Kong 234
DE - Germania 114
FR - Francia 83
FI - Finlandia 78
GB - Regno Unito 68
IN - India 64
BD - Bangladesh 61
NL - Olanda 59
SE - Svezia 53
IQ - Iraq 51
PL - Polonia 50
RU - Federazione Russa 49
UA - Ucraina 48
CA - Canada 44
TR - Turchia 40
PH - Filippine 33
JP - Giappone 32
ID - Indonesia 30
AR - Argentina 27
MX - Messico 25
EC - Ecuador 24
MY - Malesia 24
PK - Pakistan 24
AT - Austria 23
SA - Arabia Saudita 22
ZA - Sudafrica 22
ES - Italia 20
CO - Colombia 19
KE - Kenya 19
AE - Emirati Arabi Uniti 18
CL - Cile 18
PE - Perù 18
BJ - Benin 17
DO - Repubblica Dominicana 17
IR - Iran 17
GT - Guatemala 16
IE - Irlanda 16
KR - Corea 16
MA - Marocco 16
PS - Palestinian Territory 16
AO - Angola 15
TH - Thailandia 15
BG - Bulgaria 14
CY - Cipro 14
ET - Etiopia 14
HU - Ungheria 14
LB - Libano 14
RO - Romania 14
RW - Ruanda 14
UZ - Uzbekistan 14
BS - Bahamas 13
CM - Camerun 13
CZ - Repubblica Ceca 13
JO - Giordania 13
KG - Kirghizistan 13
MK - Macedonia 13
ML - Mali 13
MU - Mauritius 13
NO - Norvegia 13
TT - Trinidad e Tobago 13
YE - Yemen 13
YT - Mayotte 13
AU - Australia 12
BO - Bolivia 12
DZ - Algeria 12
EG - Egitto 12
HR - Croazia 12
IL - Israele 12
KZ - Kazakistan 12
PT - Portogallo 12
AM - Armenia 11
BF - Burkina Faso 11
CV - Capo Verde 11
GN - Guinea 11
GR - Grecia 11
MR - Mauritania 11
MZ - Mozambico 11
PY - Paraguay 11
SI - Slovenia 11
TJ - Tagikistan 11
TN - Tunisia 11
UG - Uganda 11
UY - Uruguay 11
AZ - Azerbaigian 10
CH - Svizzera 10
CI - Costa d'Avorio 10
CW - ???statistics.table.value.countryCode.CW??? 10
HN - Honduras 10
LA - Repubblica Popolare Democratica del Laos 10
LU - Lussemburgo 10
NP - Nepal 10
PR - Porto Rico 10
VE - Venezuela 10
AL - Albania 9
Totale 8.110
Città #
Ashburn 512
Singapore 479
San Jose 429
Fairfield 292
Chandler 235
Hong Kong 204
Ho Chi Minh City 194
Hanoi 146
Seattle 138
Cambridge 131
Houston 119
Woodbridge 105
Los Angeles 104
Beijing 96
Ann Arbor 93
Wilmington 75
Santa Clara 66
New York 51
Boardman 49
Munich 46
Helsinki 45
Padova 45
Milan 44
Da Nang 42
Chicago 38
Lauterbourg 36
San Diego 33
São Paulo 31
Bytom 30
Guangzhou 29
Medford 29
Princeton 29
Council Bluffs 26
Orem 26
Haiphong 24
Des Moines 23
Rome 21
Turin 21
Tokyo 20
Baghdad 19
Verona 18
Buffalo 17
Cotonou 17
Hefei 16
Nairobi 16
Turku 16
Vienna 16
Brooklyn 15
Frankfurt am Main 15
London 15
Montreal 15
The Dalles 15
Istanbul 14
Kuala Lumpur 14
Warsaw 14
Dublin 13
Lahore 13
Nassau 13
Addis Ababa 12
Amman 12
Atlanta 12
Bamako 12
Bishkek 12
Dhaka 12
Kigali 12
Luanda 12
Stockholm 12
Biên Hòa 11
Conakry 11
Dushanbe 11
Kampala 11
Montevideo 11
Redondo Beach 11
Tashkent 11
Toronto 11
Abidjan 10
Dallas 10
Florence 10
Lima 10
Nouakchott 10
Nuremberg 10
Paris 10
Shanghai 10
Sofia 10
Baku 9
Bologna 9
Hải Dương 9
Johannesburg 9
Lappeenranta 9
Manchester 9
Ninh Bình 9
Panama City 9
Santo Domingo 9
Ulan Bator 9
Zagreb 9
Ankara 8
Bangkok 8
Bridgetown 8
Castries 8
Chennai 8
Totale 4.872
Nome #
Nasal polyps in eosinophilic granulomatosis with polyangiitis: structured histopathology and CD105 expression 418
Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors 300
No differences in nasal tissue inflammatory cells and adhesion molecules (iCAM-1 and vCAM-1) comparing EGPA with eosinophilic chronic sinusitis with polyposis. 290
Fully integrated 18f-fdg pet/mr in large vessel vasculitis 289
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study 282
SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients 272
Cocaine- and Levamisole-Induced Vasculitis: Defining the Spectrum of Autoimmune Manifestations 265
Update on Vertigo in Autoimmune Disorders, from Diagnosis to Treatment 264
Overall Disability Sum Score for Clinical Assessment of Neurological Involvement in Eosinophilic Granulomatosis with Polyangiitis 263
The role of 18FDG-PET imaging in VEXAS syndrome: a multicentric case series and a systematic review of the literature 251
Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and how it determines disease severity and long-term outcomes 246
Cogan's syndrome: new therapeutic approaches in the biological era 245
A new cytological approach to improve the final diagnosis of Eosinophilic Granulomatosis with Polyangiitis (EGPA) 241
The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU) 241
Health-Related Quality of Life in Patients With ANCA-Associated Vasculitis and Sinonasal Involvement: A Single-Center Cross-Sectional Study 241
Il ruolo della 18F FDG-PET/RM nella diagnosi e gestione dei pazienti affetti da vasculiti dei grossi vasi 235
Diagnostic and prognostic role of renal histopathology in rheumatic diseases 230
Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study 223
Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis 221
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence 210
Fully integrated 18F-FDG PET/MR in large vessel vasculitis 205
Current clinical and therapeutic approach to tumour-like mass lesions in granulomatosis with polyangiitis 203
Disease and treatment-related morbidity in young and elderly patients with granulomatosis with polyangiitis and microscopic polyangiitis 202
Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) 200
Neutrophil infiltrates and eosinophil aggregates in chronic rhinosinusitis with nasal polyps and EGPA. 196
New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort 191
Ear, nose, and throat in ANCA-associated vasculitis: a comprehensive review 190
Expanding the VEXAS diagnostic workup: the role of peripheral blood cytological analysis 189
PERSISTENT LOW-GRADE VASCULAR INFLAMMATION IN LARGE VESSEL VASCULITIS: A LONGITUDINAL STUDY USING FULLY INTEGRATED 18F-FDG PET/MR 187
Anti-neutrophil cytoplasmic antibody specificity determines a different clinical subset in granulomatosis with polyangiitis 185
IgG anti-Pentraxin 3 antibodies are a novel biomarker of ANCA-associated vasculitis and better identify patients with eosinophilic granulomatosis with polyangiitis 173
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study 157
Renal involvement at baseline can predict major renal relapse in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis 156
Whipple's aortitis 152
Biologic therapy in relapsing polychondritis: navigating between options 150
Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies 143
Epstein–Barr virus-positive lymphoproliferative disorder mimicking eosinophilic granulomatosis with polyangiitis 140
Combination of monoclonal antibodies targeting type 2 inflammation for severe asthma and eosinophilic granulomatosis with polyangiitis 132
Cutting-Edge Strategies for Renal Tumour-like Lesions in Granulomatosis with Polyangiitis: A Systematic Review 119
Management of critically ill surgical patients 101
Totale 8.598
Categoria #
all - tutte 23.917
article - articoli 23.456
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.373


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202142 0 0 0 0 0 0 0 0 0 0 0 42
2021/2022476 14 35 39 34 34 60 34 38 42 15 26 105
2022/2023415 77 57 20 62 49 39 9 20 35 5 36 6
2023/2024349 6 24 32 18 22 48 44 31 31 48 25 20
2024/20251.271 18 54 63 105 140 46 85 109 69 83 211 288
2025/20265.053 318 392 625 718 420 183 1.005 379 529 276 190 18
Totale 8.598